

ASX Announcement

Wednesday 12 October 2022

**TISSUE REPAIR ANNOUNCES PEER REVIEWED JOURNAL PUBLICATION ON THE USE OF TR987® TO ASSIST SKIN HEALING FOLLOWING LASER SKIN RESURFACING PROCEDURES**


Tissue Repair Limited is pleased to announce that an article reporting the findings of a phase 2 clinical trial which used TR987® in patients who had undergone CO<sub>2</sub> fractionated laser skin resurfacing treatment has been accepted for publication in the highly regarded, peer reviewed journal of Dermatologic Surgery and will be available online from December 2022.

TR987® contains the Company's patented Glucoprime® ingredient, which will also be used in the Company's branded product, TR Pro+™, due to be launched commercially early next calendar year in Australia.

The trial was a single-centre, randomised, double-blinded study which compared TR987® against placebo in 42 healthy females. Skin quality was assessed by the validated 3- and 9-point Fitzpatrick-Goldman Wrinkle and Elastosis Scale (respectively) to evaluate the effectiveness of TR Pro+ in promoting post-procedure healing. Elastosis and Wrinkling are the two core attributes used to measure improvement in skin quality.

For wrinkling, 85% of responders achieved a score of 1 or greater (i.e. 33% improvement) in the active group compared to the placebo group where only 50% of responders had a score of 1 or greater. The absolute difference of 35.0% is statistically significant (p = 0.041).

In regard to elastosis, 75% of responders achieved an improvement score of 3 or greater (i.e. 33% improvement) for the active group compared to the placebo group where only



**Tissue Repair Ltd**

Level 10, 255 Pitt Street, Sydney, NSW 2000

ACN: 158 411 566



35% of responders achieved the same level of improvement. The absolute difference of 40.0% is statistically significant ( $p = 0.011$ ).

Publication of this study provides further evidence of the benefits of TR Pro+™ in assisting skin healing and improving skin quality.

Tissue Repair also expects to report on the results of their recently completed real-world evidence study soon in which 12 dermatology clinics trialled TR Pro+™ with patients who had undergone a range of procedures including ablative and non-ablative laser, skin needling, light therapy treatments as well as skin cancer removal.

For further information in relation to this release please contact Darryl Reed at [darryl.reed@trtherapeutics.com](mailto:darryl.reed@trtherapeutics.com) - 0419 557 663.

*This announcement has been approved for release by TRP's board.*

--ENDS--

#### **About Tissue Repair**

Tissue Repair Limited (ASX:TRP) is an advanced biotechnology company developing second generation wound healing agents. The Company's core focus is entering a phase 3 program in chronic wounds for its lead drug candidate TR-987®, with a secondary focus on commercialising TR Pro+™ a post procedure topical gel to accelerate healing and improve skin quality post any cosmetic procedure. The Company's longer-term strategy is to commercialise its propriety Glucoprime® API to treat a variety of wounds and skin conditions.



**Tissue Repair Ltd**

Level 10, 255 Pitt Street, Sydney, NSW 2000

ACN: 158 411 566